COST UTILITY ANALYSIS OF HPV VACCINATION WITH BIVALENT AS04 ADJUVANT VACCINE IN SLOVAKIA AND IMPACT OF VACCINE PROTECTION DURATION ON COST-EFFECTIVENESS ENDPOINTS

被引：0
|
作者：
Bielik, J. [1 ]
Foltan, V [2 ]
Psenkova, M. [3 ]
Hroncova, D. [4 ]
Marusakova, E. [5 ]
Sadovsky, O. [6 ]
机构：
[1] Fac Hlth, Trencin, Slovakia
[2] Comenius Univ, Bratislava, Slovakia
[3] Spol S Ro, Pharm In, Bratislava, Slovakia
[4] GSK, Noncommercial Educ Ctr, Bratislava, Slovakia
[5] GlaxoSmithKline Slovakia, Bratislava, Slovakia
[6] Natl Oncol Inst, Bratislava, Slovakia
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)73257-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A541 / A542
页数：2
相关论文
共 50 条
  • [31] A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme
    Dee, Anne
    Howell, Fenton
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2010, 20 (02): : 213 - 219
  • [32] The introduction of the bivalent ajuvant anti HPV vaccine with AS04 in the Italian regions: economic impact and effects on women's health
    Cavallo, Maria Caterina
    Cipriani, Filippo
    Gerzeli, Simone
    Demarteau, Nadia
    Marocco, Alessia
    Bamfi, Francesco
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2008, 9 : 3 - 10
  • [33] Nonavalent HPV vaccine's cost-effectiveness for Norway remains to be determined
    Goodman, Elizabeth
    Daniels, Vincent
    Rauscher, Andreas
    Stanley, Margaret
    PREVENTIVE MEDICINE, 2021, 150
  • [34] COST-EFFECTIVENESS OF THE VACCINE AGAINST HPV 16 AND 18 SUBTYPES IN MEXICO
    Mucino-Ortega, E.
    Valencia-Mendoza, A.
    Flores-Leonard, Y.
    Bertozzi Kenefick, S. M.
    VALUE IN HEALTH, 2011, 14 (07) : A538 - A538
  • [35] ESTIMATING THE COST-EFFECTIVENESS PROFILE OF A UNIVERSAL VACCINATION PROGRAMME WITH A NINE-VALENT HPV VACCINE IN AUSTRIA
    Boiron, L.
    Joura, E.
    Largeron, N.
    Prager, B.
    Nikoglou, T.
    VALUE IN HEALTH, 2015, 18 (07) : A585 - A585
  • [36] Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
    Boiron, L.
    Joura, E.
    Largeron, N.
    Prager, B.
    Uhart, M.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [37] COMPARING VACCINE EFFECTIVENESS ESTIMATES IN COST-EFFECTIVENESS ANALYSES OF PNEUMOCOCCAL VACCINATION IN ADULTS
    Yang, H. K.
    Mauskopf, J. A.
    Dasbach, E.
    VALUE IN HEALTH, 2013, 16 (03) : A17 - A17
  • [38] Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
    L. Boiron
    E. Joura
    N. Largeron
    B. Prager
    M. Uhart
    BMC Infectious Diseases, 16
  • [39] Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study
    Gao, Meng
    Hu, Shangying
    Zhao, Xuelian
    You, Tingting
    Hong, Yuting
    Liu, Yang
    Qiao, Youlin
    Jit, Mark
    Zhao, Fanghui
    Wang, Chen
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2025, 56
  • [40] COST-EFFECTIVENESS ANALYSIS OF QUADRIVALENT INFLUENZA VACCINE IN SPAIN
    Garcia Rojas, A.
    Ortiz de Lejarazu, R. L.
    Reina, J.
    Callejo, D.
    Cuervo Uria, J.
    Morano Larragueta, R.
    VALUE IN HEALTH, 2015, 18 (07) : A588 - A588
12345